A human intervention study in adults from the general population experiencing bloating, abdominal pain and flatulence found that daily supplementation with B-GOS led to statistically significant reductions in these symptoms within 7 days, with further improvements maintained into week two.

• Conducted in adults with real-world digestive discomfort (not clinical IBS only)
• Significant reductions in bloating, flatulence and abdominal pain scores
• Improvements observed within 1 week, sustained at 2 weeks
• No significant changes in stool frequency — suggesting targeted symptom relief rather than laxative effect
• Placebo-controlled design

 https://pubmed.ncbi.nlm.nih.gov/30109908/

You’re likely to feel a difference relatively quickly — particularly less bloating and discomfort — without harsh or disruptive effects on digestion.

A randomised, placebo-controlled clinical trial in individuals with IBS showed that daily supplementation with trans-galactooligosaccharide significantly increased levels of beneficial bifidobacteria and improved key symptoms including bloating, flatulence and stool consistency, particularly at a 3.5g daily dose.

• Conducted in IBS-diagnosed patients (higher symptom severity)
• Dose-dependent effect, with strongest results at ~3.5g/day
• Significant improvements in:
• Bloating
• Flatulence
• Stool consistency
• Demonstrated direct link between microbiome changes and symptom relief
• Randomised, placebo-controlled design

https://pubmed.ncbi.nlm.nih.gov/19053980/

If it works in more sensitive, IBS-type guts, it’s strong evidence it can help with everyday bloating and digestive discomfort.

A randomised, double-blind, placebo-controlled crossover study in healthy adults demonstrated that B-GOS acts as a selective prebiotic, significantly increasing populations of bifidobacteria without stimulating less desirable bacterial groups.

• Crossover design (participants act as their own control → stronger data)
• Selective stimulation of bifidobacteria (key beneficial species)
• No broad overgrowth of other bacteria → targeted microbiome effect
• Conducted in healthy adults, showing baseline gut improvement
• Establishes mechanism of action, not just outcome

https://pubmed.ncbi.nlm.nih.gov/18326619/

Rather than adding bacteria, it feeds the right ones already in your gut — helping restore balance naturally.

A 12-week randomised, double-blind, placebo-controlled crossover study in 45 overweight adults found that B-GOS increased bifidobacteria and led to improvements in markers including C-reactive protein (CRP), insulin levels, total cholesterol and triglycerides.

• 12-week duration (longer-term intervention)
• Participants had elevated metabolic risk factors
• Observed reductions in:
• CRP (inflammation marker)
• Insulin
• Total cholesterol
• Triglycerides
• Increased bifidobacteria linked to these changes
• Suggests gut-driven systemic effects

https://pubmed.ncbi.nlm.nih.gov/23303873/

Shows gut health doesn’t just affect digestion — it can influence broader health markers linked to inflammation and metabolism.

A randomised, double-blind, placebo-controlled study in 159 travellers found that those taking B-GOS experienced lower incidence and shorter duration of travellers’ diarrhoea, alongside reduced abdominal pain and better overall wellbeing.

• Large sample size (n=159)
• Real-world high-stress gut environment (travel)
• Reduced:
• Diarrhoea incidence
• Duration of symptoms
• Abdominal pain
• Improved quality-of-life scores

https://pubmed.ncbi.nlm.nih.gov/19756029/

Supports gut resilience under stress — useful beyond travel (diet changes, alcohol, busy routines).

A follow-up randomised, placebo-controlled study showed that B-GOS reduced the likelihood of diarrhoea episodes, with protective effects becoming apparent after approximately one week of consistent supplementation.

• Reinforces time-dependent effect
• Protection strongest with high compliance
• Focus on short-duration diarrhoea reduction
• Complements earlier travel study

https://pubmed.ncbi.nlm.nih.gov/28931149/

This isn’t a quick fix - it works by building your gut’s resilience over time.

A double-blind, placebo-controlled crossover study in elderly individuals showed that B-GOS increased bifidobacteria and improved immune markers, including increased natural killer (NK) cell activity and a shift toward anti-inflammatory cytokine profiles.

• Increased NK cell activity (frontline immune defence)
• Higher IL-10 (anti-inflammatory)
• Lower pro-inflammatory markers
• Strong gut-immune link demonstrated
• Controlled crossover design

https://pubmed.ncbi.nlm.nih.gov/26218845/

Supports immune function through improving gut balance — particularly relevant for long-term health.

A study in healthy elderly volunteers found that B-GOS supplementation significantly altered gut microbiota composition and positively influenced immune function markers.

• Increased bifidobacteria levels
• Changes in immune response markers
• Demonstrates link between ageing microbiome and immunity
• Controlled intervention study

https://pubmed.ncbi.nlm.nih.gov/18996881/

Reinforces that supporting your gut can have wider effects on immune health.

 Randomised study comparing B-GOS supplementation with a low-FODMAP diet in IBS patients, measuring effects on gut microbiota, gas production and digestive sensations over 4 weeks.

• Conducted in IBS patients (clinically sensitive population)
• Compared directly against low-FODMAP diet (gold standard approach)
• Measured Gut microbiota composition, Gas production and Digestive sensations
• Demonstrates diet vs microbiome intervention comparison

https://pubmed.ncbi.nlm.nih.gov/29964041/

Supports the idea that improving gut bacteria can play a role in managing digestive sensitivity — not just restricting foods.

A randomised, placebo-controlled trial in 45 healthy adults found that B-GOS supplementation over three weeks reduced the cortisol awakening response and influenced emotional processing, compared to both placebo and another prebiotic (FOS).

• 45 healthy participants
• 3-week intervention
• Measured biological stress marker (cortisol)
• Compared vs placebo and FOS
• Observed changes in emotional processing bias

https://pubmed.ncbi.nlm.nih.gov/25449699/

Suggests that gut health may influence how the body responds to stress, reinforcing the link between the gut and brain.

This study investigated the effect of B-GOS supplementation on airway inflammation and hyperpnoea-induced bronchoconstriction (a model for exercise-induced breathing stress), exploring how gut microbiota may influence immune responses beyond the digestive system.

• Focus on gut-lung axis
• Measured airway inflammation and bronchoconstriction
• Demonstrates systemic immune effects linked to gut microbiota
• Controlled intervention design

https://pubmed.ncbi.nlm.nih.gov/27523186/

Reinforces that gut health has wider effects across the body, particularly in how the immune system responds to stressors.

A 6-week intervention in children with autism spectrum disorder found that B-GOS altered gut microbiota composition and metabolic activity, with reported improvements in behavioural measures, particularly when combined with dietary interventions.

• 30 participants (ASD population)
• 6-week intervention
• Changes in gut microbiota + metabolites
• Behavioural improvements reported
• Stronger effects alongside dietary changes

https://pubmed.ncbi.nlm.nih.gov/30071894/

Adds to growing evidence that the gut microbiome may influence brain function — though this is still an emerging area of research.

A randomised controlled trial explored the effects of B-GOS supplementation on cognitive function in individuals with psychosis. While limited detail is available from the abstract, the study suggests potential improvements in cognitive outcomes linked to gut microbiota changes.

• Randomised controlled design
• Focus on cognition in clinical population
• Explores gut-brain relationship
• Limited publicly available detail

https://pubmed.ncbi.nlm.nih.gov/30876680/

Supports early-stage research into how gut health may influence cognitive function, but not suitable for direct consumer claims.